Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 10, 2012 - Issue 4
Submit an article Journal homepage
1,730
Views
159
CrossRef citations to date
0
Altmetric
Reviews

Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

George G Zhanel Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Medicine, Health Sciences Centre, Winnipeg, MB, Canada; Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada. [email protected]
,
Christopher D Lawson Faculty of Pharmacy, University of Manitoba, Winnipeg, MB, Canada; Faculty of Pharmacy, University of Manitoba, Winnipeg, MB, Canada
,
Sheryl Zelenitsky Faculty of Pharmacy, University of Manitoba, Winnipeg, MB, Canada; Faculty of Pharmacy, University of Manitoba, Winnipeg, MB, Canada
,
Brandon Findlay Department of Chemistry, Faculty of Science, University of Manitoba, Winnipeg, MB, Canada; Department of Chemistry, Faculty of Science, University of Manitoba, Winnipeg, MB, Canada
,
Frank Schweizer Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Chemistry, Faculty of Science, University of Manitoba, Winnipeg, MB, Canada; Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Chemistry, Faculty of Science, University of Manitoba, Winnipeg, MB, Canada
,
Heather Adam Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, MB, Canada; Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, MB, Canada
,
Andrew Walkty Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, MB, Canada; Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, MB, Canada
,
Ethan Rubinstein Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Medicine, Health Sciences Centre, Winnipeg, MB, Canada; Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Medicine, Health Sciences Centre, Winnipeg, MB, Canada
,
Alfred S Gin Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Faculty of Pharmacy, University of Manitoba, Winnipeg, MB, Canada; Department of Pharmacy, Health Sciences Centre, Winnipeg, MB, Canada; Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Faculty of Pharmacy, University of Manitoba, Winnipeg, MB, Canada; Department of Pharmacy, Health Sciences Centre, Winnipeg, MB, Canada
,
Daryl J Hoban Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, MB, Canada; Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, MB, Canada
,
Joseph P Lynch Division of Pulmonary, Department of Critical Care, Allergy and Clinical Immunology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Pulmonary, Department of Critical Care, Allergy and Clinical Immunology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
&
James A Karlowsky Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, MB, Canada; Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, MB, Canada
 show all
Pages 459-473 | Published online: 10 Jan 2014

Citations (159)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (25)

Coleman Rotstein, Joseph P. Lynch$suffix/text()$suffix/text() & George G. Zhanel. (2023) Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials. Expert Review of Anti-infective Therapy 21:11, pages 1213-1225.
Read now
Mona Abd El-Aziz Gadallah, Wasila Moursy El-sayed, Mohammed Zakaria Hussien, Mohammed Ahmed Elheniedy & Sara Youssef Maxwell. (2023) In-vitro activity of plazomicin, meropenem-vaborbactam, and omadacycline against carbapenem-resistant Gram-negative isolates in Egypt. Journal of Chemotherapy 35:3, pages 205-218.
Read now
Joseph P. Lynch$suffix/text()$suffix/text(), Nina M. Clark & George G. Zhanel. (2021) Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases. Expert Opinion on Pharmacotherapy 22:11, pages 1455-1474.
Read now
Anastasia Bilinskaya, Kristin E. Linder & Joseph L. Kuti. (2020) Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections. Expert Review of Anti-infective Therapy 18:8, pages 705-720.
Read now
Emel Mataraci Kara, Mesut Yilmaz, Ayşe Istanbullu Tosun & Berna Özbek Çelik. (2020) Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. Journal of Chemotherapy 32:4, pages 171-178.
Read now
Abdullah Tarık Aslan & Murat Akova. (2019) Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options. Expert Review of Anti-infective Therapy 17:12, pages 969-981.
Read now
Georgios L. Voulgaris, Maria L. Voulgari & Matthew E. Falagas. (2019) Developments on antibiotics for multidrug resistant bacterial Gram-negative infections. Expert Review of Anti-infective Therapy 17:6, pages 387-401.
Read now
Daniele Roberto Giacobbe, Malgorzata Mikulska & Claudio Viscoli. (2018) Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Review of Clinical Pharmacology 11:12, pages 1219-1236.
Read now
Lindsay M. Avery & David P. Nicolau. (2018) Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Expert Opinion on Investigational Drugs 27:4, pages 325-338.
Read now
James M. Kidd, Joseph L. Kuti & David P. Nicolau. (2018) Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. Expert Opinion on Pharmacotherapy 19:4, pages 397-408.
Read now
Alexandre P. Zavascki, Brandon O. Klee & Jürgen B. Bulitta. (2017) Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Review of Anti-infective Therapy 15:6, pages 519-526.
Read now
Joshua T. Thaden, Jason M. Pogue & Keith S. Kaye. (2017) Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 8:4, pages 403-416.
Read now
Matthew E. Falagas, Andreas D. Mavroudis & Konstantinos Z. Vardakas. (2016) The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?. Expert Review of Anti-infective Therapy 14:8, pages 747-763.
Read now
Adamantia Liapikou & Antoni Torres. (2016) Emerging drugs for nosocomial pneumonia. Expert Opinion on Emerging Drugs 21:3, pages 331-341.
Read now
Vicenç Falcó, Joaquin Burgos, Elisabeth Papiol, Ricard Ferrer & Benito Almirante. (2016) Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia. Expert Opinion on Investigational Drugs 25:6, pages 653-665.
Read now
Federico Perez, Nadim G. El Chakhtoura, Krisztina M. Papp-Wallace, Brigid M. Wilson & Robert A. Bonomo. (2016) Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy?. Expert Opinion on Pharmacotherapy 17:6, pages 761-781.
Read now
Shang-Yi Lin, Chung-Hao Huang, Wen-Chien Ko, Yen-Hsu Chen & Po-Ren Hsueh. (2016) Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections. Expert Opinion on Pharmacotherapy 17:3, pages 339-354.
Read now
Ilias Karaiskos, Maria Souli & Helen Giamarellou. (2015) Plazomicin: an investigational therapy for the treatment of urinary tract infections. Expert Opinion on Investigational Drugs 24:11, pages 1501-1511.
Read now
Ilias Karaiskos & Helen Giamarellou. (2014) Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opinion on Pharmacotherapy 15:10, pages 1351-1370.
Read now
Vincent Cattoir & Jean-Christophe Giard. (2014) Antibiotic resistance in Enterococcus faecium clinical isolates. Expert Review of Anti-infective Therapy 12:2, pages 239-248.
Read now
Ze-Qi Xu, Michael T Flavin & John Flavin. (2014) Combating multidrug-resistant Gram-negative bacterial infections. Expert Opinion on Investigational Drugs 23:2, pages 163-182.
Read now
Heather Conway, Kelly J. Dix, Jacob D. McDonald, Rodney A. Miller, Henry G. Wall, Ronald K. Wolff & Matthew D. Reed. (2013) Comparison of inhalation toxicity studies of gentamicin in rats and dogs. Inhalation Toxicology 25:13, pages 714-724.
Read now
Lee P Skrupky, Bethany R Tellor & John E Mazuski. (2013) Current strategies for the treatment of complicated intraabdominal infections. Expert Opinion on Pharmacotherapy 14:14, pages 1933-1947.
Read now
Ian M. Gould & Abhijit M. Bal. (2013) New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 4:2, pages 185-191.
Read now
Rafael Cantón & Jenny Bryan. (2012) Global antimicrobial resistance: from surveillance to stewardship. Part 2: stewardship initiatives. Expert Review of Anti-infective Therapy 10:12, pages 1375-1377.
Read now

Articles from other publishers (134)

Mohammad Saydur Rahman, Gazi Mohammad Al Amin, Shah Mohammad Anwar, Mohammad Ferdaus Azam, Fatema Akhter, Mohammad Rabiul Islam & Young-Sang Koh. (2023) Plazomicin—a New Aminoglycoside—for Treating Complicated Urinary Tract Infections. Journal of Bacteriology and Virology 53:1, pages 1-10.
Crossref
Marta Palau, Estela Muñoz, Muriel F. Gusta, Nieves Larrosa, Xavier Gomis, Joan Gilabert, Benito Almirante, Victor Puntes, Robert Texidó & Joan Gavaldà. (2023) In Vitro Antibacterial Activity of Silver Nanoparticles Conjugated with Amikacin and Combined with Hyperthermia against Drug-Resistant and Biofilm-Producing Strains . Microbiology Spectrum 11:3.
Crossref
Shiv Dhiman, Danyel Ramirez, Yanqi Li, Ayush Kumar, Gilbert Arthur & Frank Schweizer. (2023) Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and β-Lactam Antibiotics against Multidrug-Resistant Pseudomonas aeruginosa . ACS Infectious Diseases 9:4, pages 864-885.
Crossref
Nitin Pal Kalia, Manoj Kumar, Souhaila Al Khodor & Sandeep Sharma. 2023. Current Trends in the Identification and Development of Antimicrobial Agents. Current Trends in the Identification and Development of Antimicrobial Agents 105 124 .
Helio S Sader, Rodrigo E Mendes, John H Kimbrough, Valerie Kantro & Mariana Castanheira. (2023) Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers. Open Forum Infectious Diseases 10:2.
Crossref
Bisma Jan, Rafia Jan, Suhaib Afzal, Mehrose Ayoub & Mubashir Hussain Masoodi. 2023. Non-traditional Approaches to Combat Antimicrobial Drug Resistance. Non-traditional Approaches to Combat Antimicrobial Drug Resistance 79 100 .
Johnny Zakhour, Sima L. Sharara, Joya-Rita Hindy, Sara F. Haddad & Souha S. Kanj. (2022) Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis. Antibiotics 11:10, pages 1432.
Crossref
Yunhao Wu, Wei Meng, Ming Guan, Xiaolong Zhao, Chen Zhang, Qiaojun Fang, Yuhua Zhang, Zihui Sun, Mingjing Cai, Dongdong Huang, Xuechun Yang, Yafeng Yu, Yong Cui, Shuangba He & Renjie Chai. (2022) Pitavastatin protects against neomycin-induced ototoxicity through inhibition of endoplasmic reticulum stress. Frontiers in Molecular Neuroscience 15.
Crossref
Ravleen Kaur, Pooja Rani, Atanas G. Atanasov, Qushmua Alzahrani, Reena Gupta, Bhupinder Kapoor, Monica Gulati & Pooja Chawla. (2022) Discovery and Development of Antibacterial Agents: Fortuitous and Designed. Mini-Reviews in Medicinal Chemistry 22:7, pages 984-1029.
Crossref
Joseph P. LynchIIIIII & George G. Zhanel. (2022) Pseudomonas aeruginosa Pneumonia: Evolution of Antimicrobial Resistance and Implications for Therapy. Seminars in Respiratory and Critical Care Medicine 43:02, pages 191-218.
Crossref
Zhuohang Yu, Zengrui Wu, Weihua Li, Guixia Liu & Yun Tang. (2022) ADENet: a novel network-based inference method for prediction of drug adverse events. Briefings in Bioinformatics 23:2.
Crossref
Andrew Chou, Elwyn Welch, Andrew Hunter & Barbara W. Trautner. (2022) Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review. Drugs 82:4, pages 407-438.
Crossref
Fan YangPing ChenHuiyuan WangXiaoyu XingSisi WangHafiz Muhammad IshaqWei Liao. (2022) Comparative Minimal Inhibitory and Mutant Prevention Concentration of Eight Antimicrobial Agents Against Klebsiella pneumoniae . Microbial Drug Resistance 28:2, pages 229-235.
Crossref
Joseph P. LynchIIIIII, Nina M. Clark & George G. Zhanel. (2022) Infections Due to Acinetobacter baumannii–calcoaceticus Complex: Escalation of Antimicrobial Resistance and Evolving Treatment Options. Seminars in Respiratory and Critical Care Medicine 43:01, pages 097-124.
Crossref
Jorge Arca-Suárez, Bruno K. Rodiño-Janeiro, Astrid Pérez, Paula Guijarro-Sánchez, Juan C. Vázquez-Ucha, Fernando Cruz, Jèssica Gómez-Garrido, Tyler S. Alioto, Miguel Álvarez-Tejado, Marta Gut, Ivo Gut, Marina Oviaño, Alejandro Beceiro, Germán Bou, Irene Merino, Emilia Cercenado, Rosa Gómez, Tamara Soler, Irene Gracia-Ahufinger, Lina Martín, Fátima Galán, Nuria Tormo, Juan Carlos Rodríguez, Silvia Capilla, Francesc Marco, María Dolores Quesada, Emma Padilla, Fe Tubau, Juanjo González, Ana Isabel López-Calleja, José Luis del Pozo, María Inmaculada García, Mariela Martinez, Jorge Calvo, Xavier Mulet, Fernanda Peña, Ana Isabel Rodríguez, María José Gude, Ana Fernández & Javier Fernández. (2022) Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing. International Journal of Antimicrobial Agents 59:1, pages 106456.
Crossref
Irfan Ahmad Khan. 2022. Beta-Lactam Resistance in Gram-Negative Bacteria. Beta-Lactam Resistance in Gram-Negative Bacteria 287 298 .
Yulong Zong, Fang Chen, Shanshan Li & Hui Zhang. (2021) (−)-Epigallocatechin-3-gallate (EGCG) prevents aminoglycosides-induced ototoxicity via anti-oxidative and anti-apoptotic pathways. International Journal of Pediatric Otorhinolaryngology 150, pages 110920.
Crossref
So-Young Ham, Han-Shin Kim, Min Jee Jo, Jeong-Hoon Lee, Youngjoo Byun, Gang-Jee Ko & Hee-Deung Park. (2021) Combined Treatment of 6-Gingerol Analog and Tobramycin for Inhibiting Pseudomonas aeruginosa Infections. Microbiology Spectrum 9:2.
Crossref
Kathleen Tompkins & David van Duin. (2021) Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. European Journal of Clinical Microbiology & Infectious Diseases 40:10, pages 2053-2068.
Crossref
Brian D. Johnston, Paul Thuras, Stephen B. Porter, Connie Clabots & James R. Johnson. (2021) Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012–2017) in relation to phylogenetic background, sequence type 131 subclones, blaCTX-M genotype, and resistance to comparator agents. European Journal of Clinical Microbiology & Infectious Diseases 40:10, pages 2069-2075.
Crossref
Brian D Johnston, Paul Thuras, Stephen B Porter, Melissa Anacker, Brittany VonBank, Paula Snippes Vagnone, Medora Witwer, Mariana Castanheira & James R Johnson. (2021) Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region . Journal of Antimicrobial Chemotherapy 76:8, pages 2061-2070.
Crossref
Favour Danladi Makurvet. (2021) Biologics vs. small molecules: Drug costs and patient access. Medicine in Drug Discovery 9, pages 100075.
Crossref
Jonás Samuel Pérez-Blanco, Eva María Sáez Fernández, María Victoria Calvo, José M. Lanao & Ana Martín-Suárez. (2021) Evaluation of Current Amikacin Dosing Recommendations and Development of an Interactive Nomogram: The Role of Albumin. Pharmaceutics 13:2, pages 264.
Crossref
Mary E. O’Sullivan, Yohan SongRobert GreenhouseRandy LinAdela PerezPatrick J. AtkinsonJacob P. MacDonaldZehra SiddiquiDennis LagascaKate ComstockMarkus E. Huth, Alan G. Cheng & Anthony J. Ricci. (2020) Dissociating antibacterial from ototoxic effects of gentamicin C-subtypes. Proceedings of the National Academy of Sciences 117:51, pages 32423-32432.
Crossref
Matteo Bassetti, Antonio Vena, Denise Battaglini, Paolo Pelosi & Daniele Roberto Giacobbe. (2020) The role of new antimicrobials for Gram-negative infections in daily clinical practice. Current Opinion in Infectious Diseases 33:6, pages 495-500.
Crossref
Dima Ibrahim, Jean-Francois Jabbour & Souha S. Kanj. (2020) Current choices of antibiotic treatment for Pseudomonas aeruginosa infections. Current Opinion in Infectious Diseases 33:6, pages 464-473.
Crossref
Temilolu Idowu, Derek Ammeter, Marc Brizuela, Gregory Jackson, Shadman Alam & Frank Schweizer. (2020) Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants. Bioorganic & Medicinal Chemistry Letters 30:21, pages 127575.
Crossref
Matteo Bassetti, Vincenzo Di Pilato, Tommaso Giani, Antonio Vena, Gian Maria Rossolini, Anna Marchese & Daniele R Giacobbe. (2020) Treatment of severe infections due to metallo-β-lactamases-producing Gram-negative bacteria. Future Microbiology 15:15, pages 1489-1505.
Crossref
Namık KILINÇ & Şükrü BEYDEMİR. (2020) The Evaluation of Inhibition Effects of Antibiotics on the Sheep Stomach Carbonic Anhydrase I and II IsozymesThe Evaluation of Inhibition Effects of Antibiotics on the Sheep Stomach Carbonic Anhydrase I and II Isozymes. Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi 10:3, pages 1811-1819.
Crossref
. (2019) Newer Antibiotics: Need for More Studies in Neonates and Children. Pediatric Infectious Disease 1:4, pages 164-168.
Crossref
Agila Kumari Pragasam, S.Lydia Jennifer, Dhanalakshmi Solaimalai, Dhiviya Prabaa Muthuirulandi Sethuvel, Tanya Rachel, Divyaa Elangovan, Karthick Vasudevan, Karthick Gunasekaran & Balaji Veeraraghavan. (2020) Expected Plazomicin Susceptibility in India Based on the Prevailing Aminoglycoside Resistance Mechanisms in Gram-Negative Organisms Derived from Whole-Genome Sequencing. Indian Journal of Medical Microbiology 38:3-4, pages 313-318.
Crossref
Mahnaz Sabeti Azad, Maho Okuda, Mélina Cyrenne, Mickael Bourge, Marie-Pierre Heck, Satoko Yoshizawa & Dominique Fourmy. (2020) Fluorescent Aminoglycoside Antibiotics and Methods for Accurately Monitoring Uptake by Bacteria. ACS Infectious Diseases 6:5, pages 1008-1017.
Crossref
Mariana Castanheira, Helio S. Sader, Rodrigo E. Mendes & Ronald N. Jones. (2020) Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016–2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides . Antimicrobial Agents and Chemotherapy 64:5.
Crossref
Temilolu Idowu, George G. Zhanel & Frank Schweizer. (2020) A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development. Antimicrobial Agents and Chemotherapy 64:3.
Crossref
Wim A. Fleischmann, Kerryl E. Greenwood-Quaintance & Robin Patel. (2020) In Vitro Activity of Plazomicin Compared to Amikacin, Gentamicin, and Tobramycin against Multidrug-Resistant Aerobic Gram-Negative Bacilli . Antimicrobial Agents and Chemotherapy 64:2.
Crossref
Girija S. Singh. 2020. Carbohydrates in Drug Discovery and Development. Carbohydrates in Drug Discovery and Development 523 559 .
Juan David Plata & Ximena Castañeda. 2020. Oncologic Critical Care. Oncologic Critical Care 1323 1335 .
Derek Ammeter, Temilolu Idowu, George G. Zhanel & Frank Schweizer. (2019) Development of a nebramine-cyclam conjugate as an antibacterial adjuvant to potentiate β-lactam antibiotics against multidrug-resistant P. aeruginosa. The Journal of Antibiotics 72:11, pages 816-826.
Crossref
Jonathan Gall, Taylor Choi, Valerie Riddle, Scott Van Wart, Jacqueline A. Gibbons & Julie Seroogy. (2019) A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics. Clinical Pharmacology in Drug Development 8:8, pages 1032-1041.
Crossref
Temilolu Idowu, Derek Ammeter, Heather Rossong, George G. Zhanel & Frank Schweizer. (2019) Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria. Journal of Medicinal Chemistry 62:20, pages 9103-9115.
Crossref
Tomefa E. Asempa, Joseph L. Kuti, Julie D. Seroogy, Allison S. Komirenko & David P. Nicolau. (2019) Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection. Antimicrobial Agents and Chemotherapy 63:10.
Crossref
Viviana G. Correia, Benedita A. Pinheiro, Ana Luísa Carvalho & Angelina S. Palma. 2019. Antibiotic Drug Resistance. Antibiotic Drug Resistance 1 38 .
Temilolu Idowu, Derek Ammeter, Gilbert Arthur, George G Zhanel & Frank Schweizer. (2019) Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin–cyclam conjugates. Journal of Antimicrobial Chemotherapy 74:9, pages 2640-2648.
Crossref
George G Zhanel, Heather J Adam, Melanie R Baxter, Jeff Fuller, Kimberly A Nichol, Andrew J Denisuik, Alyssa R Golden, Rachel Hink, Philippe R S Lagacé-Wiens, Andrew Walkty, Michael R Mulvey, Frank Schweizer, Denice Bay, Daryl J Hoban, James A Karlowsky, George G Zhanel, Daryl J Hoban, Heather J Adam, Melanie R Baxter, Kimberly A Nichol, Philippe R S Lagacé-Wiens, Andrew Walkty, James A Karlowsky, J Blondeau, R Slinger, R Davidson, G Zhanel, D Hoban, J Delport, C Ellis, M Laverdière, V Loo, S Poutanen, J Fuller, D Roscoe, M Desjardins, L Matukas, M Goyette, C Lee, A Carignan, M Bergevin & R Pelletier. (2019) 42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance study. Journal of Antimicrobial Chemotherapy 74:Supplement_4, pages iv5-iv21.
Crossref
Tomefa E. Asempa, Joseph L. Kuti, Julie D. Seroogy, Allison S. Komirenko & David P. Nicolau. (2019) A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. Clinical Therapeutics 41:8, pages 1453-1462.
Crossref
Taylor Choi, Allison S. Komirenko, Valerie Riddle, Aryun Kim & Shyeilla V. Dhuria. (2019) No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. Clinical Pharmacology in Drug Development 8:6, pages 818-826.
Crossref
Ilias Karaiskos, Styliani Lagou, Konstantinos Pontikis, Vasiliki Rapti & Garyphallia Poulakou. (2019) The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Frontiers in Public Health 7.
Crossref
Andrew Walkty, James A. Karlowsky, Melanie R. Baxter, Heather J. Adam, David Boyd, Amrita Bharat, Michael R. Mulvey, Marthe Charles, Marco Bergevin & George G. Zhanel. (2019) Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013–2017). Diagnostic Microbiology and Infectious Disease 94:2, pages 199-201.
Crossref
Manouchehr Khazandi, Hongfei Pi, Wei Yee Chan, Abiodun David Ogunniyi, Jowenna Xiao Feng Sim, Henrietta Venter, Sanjay Garg, Stephen W. Page, Peter B. Hill, Adam McCluskey & Darren J. Trott. (2019) In vitro Antimicrobial Activity of Robenidine, Ethylenediaminetetraacetic Acid and Polymyxin B Nonapeptide Against Important Human and Veterinary Pathogens. Frontiers in Microbiology 10.
Crossref
Fernanda I. Saldívar-González, B. Angélica Pilón-Jiménez & José L. Medina-Franco. (2019) Chemical space of naturally occurring compounds. Physical Sciences Reviews 4:5.
Crossref
Matteo Bassetti, Maddalena Peghin, Antonio Vena & Daniele Roberto Giacobbe. (2019) Treatment of Infections Due to MDR Gram-Negative Bacteria. Frontiers in Medicine 6.
Crossref
Lenhard, Bulman, Tsuji & Kaye. (2019) Shifting Gears: The Future of Polymyxin Antibiotics. Antibiotics 8:2, pages 42.
Crossref
Michael Trang, Julie D. Seroogy, Scott A. Van Wart, Sujata M. Bhavnani, Aryun Kim, Jacqueline A. Gibbons, Paul G. Ambrose & Christopher M. Rubino. (2019) Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies. Antimicrobial Agents and Chemotherapy 63:4.
Crossref
Sarah E. Costello, Lalitagauri M. Deshpande, Andrew P. Davis, Rodrigo E. Mendes & Mariana Castanheira. (2019) Aminoglycoside-modifying enzyme and 16S ribosomal RNA methyltransferase genes among a global collection of Gram-negative isolates. Journal of Global Antimicrobial Resistance 16, pages 278-285.
Crossref
Despoina Koulenti, Andrew Song, Aaron Ellingboe, Mohd Hafiz Abdul-Aziz, Patrick Harris, Emile Gavey & Jeffrey Lipman. (2019) Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?. International Journal of Antimicrobial Agents 53:3, pages 211-224.
Crossref
Andrew Walkty, James A. Karlowsky, Melanie R. Baxter, Heather J. Adam & George G. Zhanel. (2019) In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study . Antimicrobial Agents and Chemotherapy 63:1.
Crossref
Kurt G. Naber & Florian M.E. Wagenlehner. (2019) Novel Antibiotics in the Treatment of Urinary Tract Infections. European Urology Focus 5:1, pages 10-12.
Crossref
Juan David Plata & Ximena Castañeda. 2019. Oncologic Critical Care. Oncologic Critical Care 1 13 .
Kristy M. Shaeer, Monika T. Zmarlicka, Elias B. Chahine, Nicholas Piccicacco & Jonathan C. Cho. (2019) Plazomicin: A Next‐Generation Aminoglycoside. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39:1, pages 77-93.
Crossref
Dandara Cassu-Corsi, Willames MBS Martins, Adriana G Nicoletti, Luiz GP Almeida, Ana TR Vasconcelos & Ana C Gales. (2018) Characterisation of plasmid-mediated rmtB-1 in Enterobacteriaceae clinical isolates from São Paulo, Brazil. Memórias do Instituto Oswaldo Cruz 113:12.
Crossref
Allison S. Komirenko, Valerie Riddle, Jacqueline A. Gibbons, Scott Van Wart & Julie D. Seroogy. (2018) A Phase 1 Study To Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function. Antimicrobial Agents and Chemotherapy 62:12.
Crossref
Christopher M. Bland, Manjunath P. Pai & Thomas P. Lodise. (2018) Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:12, pages 1229-1238.
Crossref
Lara Rajeev. (2018) Antibiotic Discovery. Materials and Methods 8.
Crossref
Mariana Castanheira, Lalitagauri M Deshpande, Leah N Woosley, Alisa W Serio, Kevin M Krause & Robert K Flamm. (2018) Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. Journal of Antimicrobial Chemotherapy.
Crossref
Kamilia Abdelraouf, Aryun Kim, Kevin M. Krause & David P. Nicolau. (2018) In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model . Antimicrobial Agents and Chemotherapy 62:8.
Crossref
Mariana Castanheira, Andrew P. Davis, Rodrigo E. Mendes, Alisa W. Serio, Kevin M. Krause & Robert K. Flamm. (2018) In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes . Antimicrobial Agents and Chemotherapy 62:8.
Crossref
Tomefa E. AsempaLindsay M. AveryJames M. KiddJoseph L. KutiDavid P. Nicolau. (2018) Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. American Journal of Health-System Pharmacy 75:14, pages 1048-1056.
Crossref
Amr Sonousi, Vikram A. Sarpe, Margarita Brilkova, Jochen Schacht, Andrea Vasella, Erik C. Böttger & David Crich. (2018) Effects of the 1- N -(4-Amino-2 S -hydroxybutyryl) and 6′- N -(2-Hydroxyethyl) Substituents on Ribosomal Selectivity, Cochleotoxicity, and Antibacterial Activity in the Sisomicin Class of Aminoglycoside Antibiotics . ACS Infectious Diseases 4:7, pages 1114-1120.
Crossref
Agila Kumari Pragasam, Balaji Veeraraghavan, E. Nalini, Shalini Anandan & Keith S. Kaye. (2018) An Update on Antimicrobial Resistance and the Role of Newer Antimicrobial Agents for Pseudomonas aeruginosa. Indian Journal of Medical Microbiology 36:3, pages 303-316.
Crossref
William Lainhart, Melanie L Yarbrough, Sophonie Jean & Carey-Ann D Burnham. (2018) New Bugs and New Drugs: Updates in Clinical Microbiology. The Journal of Applied Laboratory Medicine 2:6, pages 925-940.
Crossref
Jesús Rodríguez-Baño, Belén Gutiérrez-Gutiérrez, Isabel Machuca & Alvaro Pascual. (2018) Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clinical Microbiology Reviews 31:2.
Crossref
Lynn E. Connolly, Valerie Riddle, Deborah Cebrik, Eliana S. Armstrong & Loren G. Miller. (2018) A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. Antimicrobial Agents and Chemotherapy 62:4.
Crossref
Nathaniel J. Rhodes, Caroline E. Cruce, J. Nicholas O’Donnell, Richard G. Wunderink & Alan R. Hauser. (2018) Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia. Current Infectious Disease Reports 20:2.
Crossref
Zoi Dorothea Pana & Theoklis Zaoutis. (2018) Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?. F1000Research 7, pages 1347.
Crossref
Yoshiaki Takahashi & Masayuki Igarashi. (2017) Destination of aminoglycoside antibiotics in the ‘post-antibiotic era’. The Journal of Antibiotics 71:1, pages 4-14.
Crossref
Sean M. Stainton & David P. Nicolau. 2018. Abdominal Sepsis. Abdominal Sepsis 249 263 .
Je Won Park, Yeon Hee Ban, Sang-Jip Nam, Sun-Shin Cha & Yeo Joon Yoon. (2017) Biosynthetic pathways of aminoglycosides and their engineering. Current Opinion in Biotechnology 48, pages 33-41.
Crossref
Appi Reddy Mandhapati, Guanyu Yang, Takayuki Kato, Dimitri Shcherbakov, Sven N. Hobbie, Andrea Vasella, Erik C. Böttger & David Crich. (2017) Structure-Based Design and Synthesis of Apramycin–Paromomycin Analogues: Importance of the Configuration at the 6′-Position and Differences between the 6′-Amino and Hydroxy Series. Journal of the American Chemical Society 139:41, pages 14611-14619.
Crossref
María Carmen López Díaz, Esther Ríos, Iciar Rodríguez-Avial, Rosa Janneth Simaluiza, Juan José Picazo & Esther Culebras. (2017) In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents. International Journal of Antimicrobial Agents 50:2, pages 191-196.
Crossref
George L Drusano. (2017) Stepping Off the Resistance Treadmill. The Journal of Infectious Diseases 216:2, pages 150-152.
Crossref
Girish C. Sati, Dimitri Shcherbakov, Sven N. Hobbie, Andrea Vasella, Erik C. Böttger & David Crich. (2017) N6′, N6′′′, and O4′ Modifications to Neomycin Affect Ribosomal Selectivity without Compromising Antibacterial Activity. ACS Infectious Diseases 3:5, pages 368-377.
Crossref
Xuan Yang, Sudeep Goswami, Bala Kishan Gorityala, Ronald Domalaon, Yinfeng Lyu, Ayush Kumar, George G. Zhanel & Frank Schweizer. (2017) A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. Journal of Medicinal Chemistry 60:9, pages 3913-3932.
Crossref
Patrice Nordmann, Aurélie Jayol, Jan Dobias & Laurent Poirel. (2017) Rapid Aminoglycoside NP Test for Rapid Detection of Multiple Aminoglycoside Resistance in Enterobacteriaceae. Journal of Clinical Microbiology 55:4, pages 1074-1079.
Crossref
Stephanie Deshayes, Wujing Xian, Nathan W. Schmidt, Shadi Kordbacheh, Juelline Lieng, Jennifer Wang, Sandra Zarmer, Samantha St. Germain, Laura Voyen, Julia Thulin, Gerard C. L. Wong & Andrea M. Kasko. (2017) Designing Hybrid Antibiotic Peptide Conjugates To Cross Bacterial Membranes. Bioconjugate Chemistry 28:3, pages 793-804.
Crossref
Tomislav Kostyanev, Marc J.M. Bonten & Herman Goossens. 2017. Anti-infectives and the Lung. Anti-infectives and the Lung 289 301 .
L. Mayrink Assis, M. Nedeljković & A. Dessen. (2017) New strategies for targeting and treatment of multi-drug resistant Staphylococcus aureus. Drug Resistance Updates 31, pages 1-14.
Crossref
Mark S Butler, Mark AT Blaskovich & Matthew A Cooper. (2016) Antibiotics in the clinical pipeline at the end of 2015. The Journal of Antibiotics 70:1, pages 3-24.
Crossref
Françoise van Bambeke, Marie-Paule Mingeot-Leclercq, Youri Glupczynski & Paul M. Tulkens. 2017. Infectious Diseases. Infectious Diseases 1162 1180.e1 .
Andrew C Pawlowski, Jarrod W Johnson & Gerard D Wright. (2016) Evolving medicinal chemistry strategies in antibiotic discovery. Current Opinion in Biotechnology 42, pages 108-117.
Crossref
Dana R. Bowers & Vanthida Huang. (2016) Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE). Current Infectious Disease Reports 18:12.
Crossref
Mélanie Wilbaux, Aline Fuchs, Janko Samardzic, Frédérique Rodieux, Chantal Csajka, Karel Allegaert, Johannes N. van den Anker & Marc Pfister. (2016) Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. The Journal of Clinical Pharmacology 56:8, pages 909-935.
Crossref
Elizabeth CerceoSteven B. DeitelzweigBradley M. ShermanAlpesh N. Amin. (2016) Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microbial Drug Resistance 22:5, pages 412-431.
Crossref
Dmitriy M. Martirosov & Thomas P. Lodise. (2016) Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease 85:2, pages 266-275.
Crossref
Mathieu F. Chellat, Luka Raguž & Rainer Riedl. (2016) Targeting Antibiotic Resistance. Angewandte Chemie International Edition 55:23, pages 6600-6626.
Crossref
Mathieu F. Chellat, Luka Raguž & Rainer Riedl. (2016) Antibiotikaresistenzen gezielt überwinden. Angewandte Chemie 128:23, pages 6710-6738.
Crossref
Guyue Cheng, Menghong Dai, Saeed Ahmed, Haihong Hao, Xu Wang & Zonghui Yuan. (2016) Antimicrobial Drugs in Fighting against Antimicrobial Resistance. Frontiers in Microbiology 7.
Crossref
Ling-Shan Syue, Yen-Hsu Chen, Wen-Chien Ko & Po-Ren Hsueh. (2016) New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. International Journal of Antimicrobial Agents 47:4, pages 250-258.
Crossref
Ali Zineddine Boumehira, Hesham Ali El-Enshasy, Hocine Hacène, Elsayed Ahmed Elsayed, Ramlan Aziz & Enoch Y. Park. (2016) Recent progress on the development of antibiotics from the genus Micromonospora. Biotechnology and Bioprocess Engineering 21:2, pages 199-223.
Crossref
Christopher Walsh. 2016. Antibiotics. Antibiotics 421 454 .
Nishad Thamban Chandrika & Sylvie Garneau-Tsodikova. (2016) A review of patents (2011–2015) towards combating resistance to and toxicity of aminoglycosides. MedChemComm 7:1, pages 50-68.
Crossref
Valjean R. Bacot-Davis, Angelia V. Bassenden & Albert M. Berghuis. (2016) Drug-target networks in aminoglycoside resistance: hierarchy of priority in structural drug design. MedChemComm 7:1, pages 103-113.
Crossref
Sylvie Garneau-Tsodikova & Kristin J. Labby. (2016) Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. MedChemComm 7:1, pages 11-27.
Crossref
Neelam YanejaHarsimran Kaur. (2016) Insights into Newer Antimicrobial Agents against Gram-negative Bacteria. Microbiology Insights 9, pages MBI.S29459.
Crossref
Jesse A. Jones, Kristopher G. Virga, Giuseppe Gumina & Kirk E. Hevener. (2016) Recent advances in the rational design and optimization of antibacterial agents. MedChemComm 7:9, pages 1694-1715.
Crossref
Thea Lu & Frank R. DeLeo. 2015. Human Emerging and Re‐emerging Infections. Human Emerging and Re‐emerging Infections 711 748 .
Selwyn Quan, Ole Skovgaard, Robert E McLaughlin, Ed T Buurman & Catherine L Squires. (2015) Markerless Escherichia coli rrn Deletion Strains for Genetic Determination of Ribosomal Binding Sites . G3 Genes|Genomes|Genetics 5:12, pages 2555-2557.
Crossref
Iciar Rodríguez-Avial, Irene Pena, Juan J. Picazo, Carmen Rodríguez-Avial & Esther Culebras. (2015) In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. International Journal of Antimicrobial Agents 46:6, pages 616-621.
Crossref
Frederique Rodieux, Melanie Wilbaux, Johannes N. van den Anker & Marc Pfister. (2015) Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. Clinical Pharmacokinetics 54:12, pages 1183-1204.
Crossref
Cristina García-Salguero, Iciar Rodríguez-Avial, Juan J. Picazo & Esther Culebras. (2015) Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?. Antimicrobial Agents and Chemotherapy 59:10, pages 5959-5966.
Crossref
Matteo Bassetti & Elda Righi. (2015) New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Current Opinion in Critical Care 21:5, pages 402-411.
Crossref
Takahiko Matsushita, Weiwei Chen, Reda Juskeviciene, Youjin Teo, Dimitri Shcherbakov, Andrea Vasella, Erik C. Böttger & David Crich. (2015) Influence of 4′- O -Glycoside Constitution and Configuration on Ribosomal Selectivity of Paromomycin . Journal of the American Chemical Society 137:24, pages 7706-7717.
Crossref
David C. McKinney, Natascha Bezdenejnih-Snyder, Krista Farrington, Jian Guo, Robert E. McLaughlin, Anatoly M. Ruvinsky, Renu Singh, Gregory S. Basarab, Sridhar Narayan & Ed T. Buurman. (2015) Illicit Transport via Dipeptide Transporter Dpp is Irrelevant to the Efficacy of Negamycin in Mouse Thigh Models of Escherichia coli Infection . ACS Infectious Diseases 1:5, pages 222-230.
Crossref
Matteo Bassetti & Elda Righi. (2015) Development of novel antibacterial drugs to combat multiple resistant organisms. Langenbeck's Archives of Surgery 400:2, pages 153-165.
Crossref
Asha S. Nayar, Thomas J. Dougherty, Folkert Reck, Jason Thresher, Ning Gao, Adam B. Shapiro & David E. Ehmann. (2015) Target-Based Resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a Novel Bacterial Type II Topoisomerase Inhibitor. Antimicrobial Agents and Chemotherapy 59:1, pages 331-337.
Crossref
Steven C. Olsen & Steve A. Carlson. (2015) In vitro bactericidal activity of aminoglycosides, including the next-generation drug plazomicin, against Brucella spp.. International Journal of Antimicrobial Agents 45:1, pages 76-78.
Crossref
Manjunath P. Pai, Mackenzie L. Cottrell, Angela D.M. Kashuba & Joseph S. BertinoJr.Jr.. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 252 262.e2 .
Winfried V. Kern. 2015. Infections in Hematology. Infections in Hematology 229 258 .
M. Bassetti, P. Della Siega & D. Pecori. 2015. Annual Update in Intensive Care and Emergency Medicine 2015. Annual Update in Intensive Care and Emergency Medicine 2015 63 83 .
Danielle R. Hirsch, Georgina Cox, Michael P. D’Erasmo, Tushar Shakya, Christine Meck, Noushad Mohd, Gerard D. Wright & Ryan P. Murelli. (2014) Inhibition of the ANT(2″)-Ia resistance enzyme and rescue of aminoglycoside antibiotic activity by synthetic α-hydroxytropolones. Bioorganic & Medicinal Chemistry Letters 24:21, pages 4943-4947.
Crossref
G. L. Drusano, W. Liu, S. Fikes, R. Cirz, N. Robbins, S. Kurhanewicz, J. Rodriquez, D. Brown, D. Baluya & A. Louie. (2014) Interaction of Drug- and Granulocyte-Mediated Killing of Pseudomonas aeruginosa in a Murine Pneumonia Model. Journal of Infectious Diseases 210:8, pages 1319-1324.
Crossref
Malcolm GP Page & Karen Bush. (2014) Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?. Current Opinion in Pharmacology 18, pages 91-97.
Crossref
Salome N. Seiffert, Jonas Marschall, Vincent Perreten, Alessandra Carattoli, Hansjakob Furrer & Andrea Endimiani. (2014) Emergence of Klebsiella pneumoniae co-producing NDM-1, OXA-48, CTX-M-15, CMY-16, QnrA and ArmA in Switzerland. International Journal of Antimicrobial Agents 44:3, pages 260-262.
Crossref
A. Walkty, H. Adam, M. Baxter, A. Denisuik, P. Lagacé-Wiens, J. A. Karlowsky, D. J. Hoban & G. G. Zhanel. (2014) In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012 . Antimicrobial Agents and Chemotherapy 58:5, pages 2554-2563.
Crossref
Mark S. Butler, Avril A. B. Robertson & Matthew A. Cooper. (2014) Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 31:11, pages 1612-1661.
Crossref
Herbert A. Kirst & Flavia Marinelli. 2014. Antimicrobials. Antimicrobials 193 209 .
Cristina de Souza Mendes & Adelaide de Souza Antunes. (2013) Pipeline of Known Chemical Classes of Antibiotics. Antibiotics 2:4, pages 500-534.
Crossref
Justin Jackson, Caroline Chen & Kirsty Buising. (2013) Aminoglycosides. Current Opinion in Infectious Diseases 26:6, pages 516-525.
Crossref
V. Cattoir. (2013) Infections à bacilles à Gram négatif résistants : nouvelles molécules, nouvelles associations. Journal des Anti-infectieux 15:4, pages 159-165.
Crossref
Mark S Butler, Mark A Blaskovich & Matthew A Cooper. (2013) Antibiotics in the clinical pipeline in 2013. The Journal of Antibiotics 66:10, pages 571-591.
Crossref
Antonis Markogiannakis, Leonidas S Tzouvelekis, Mina Psichogiou, Efi Petinaki & George L Daikos. (2013) Confronting carbapenemase-producing Klebsiella pneumoniae . Future Microbiology 8:9, pages 1147-1161.
Crossref
Paul Anantharajah Tambyah, Gabriel Levy Hara, George L. Daikos, Matthew E. Falagas, Teresita Mazzei, Johan W. Mouton, Andrea Novelli, Baiyi Chen, Minggui Wang, Wen-Chien Ko, Taisheng Li, Xinjian Fan & Ursula Theuretzbacher. (2013) Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012. Journal of Global Antimicrobial Resistance 1:3, pages 117-122.
Crossref
Kristin J Labby & Sylvie Garneau-Tsodikova. (2013) Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections. Future Medicinal Chemistry 5:11, pages 1285-1309.
Crossref
Bernd Becker & Matthew A. Cooper. (2012) Aminoglycoside Antibiotics in the 21st Century. ACS Chemical Biology 8:1, pages 105-115.
Crossref
Matteo Bassetti, Maria Merelli, Chiara Temperoni & Augusta Astilean. (2013) New antibiotics for bad bugs: where are we?. Annals of Clinical Microbiology and Antimicrobials 12:1, pages 22.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.